Picture of 4D Molecular Therapeutics logo

FDMT — 4D Molecular Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

4D Molecular Therapeutics Q3 net loss widens on higher costs

4D Molecular Therapeutics Q3 net loss widens on higher costs


Overview

  • US gene therapy developer's Q3 revenue rose, beating analyst expectations

  • Q3 net loss and operating income missed analyst estimates

  • Collaboration revenue growth driven by clinical trial cost sharing and reimbursement from Otsuka


Outlook

  • Company expects topline data from 4FRONT-1 Phase 3 trial in Q2 2027

  • Topline data from 4FRONT-2 Phase 3 trial expected in H2 2027

  • Company expects cash position to fund operations into second half of 2028


Result Drivers

  • CLINICAL TRIAL COST SHARING - Increase in collaboration and license revenue was primarily due to clinical trial cost sharing and reimbursement from Otsuka

  • PHASE 3 TRIAL EXECUTION - Higher R&D expenses were mainly driven by execution of 4D-150 Phase 3 clinical trials in wet AMD


Company press release: ID:nGNXbghDsk


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$4.15 mln

$2.70 mln (9 Analysts)

Q3 Net Loss

Miss

$78.06 mln

$74.21 mln (5 Analysts)

Q3 Operating Income

Miss

-$81.22 mln

-$79.03 mln (6 Analysts)

Q3 Loss Per Basic Share

$1.08

Q3 Operating Expenses

$85.36 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $28.00, about 115.6% above its November 11 closing price of $12.99


Reuters Recommended Reads

  • Nov 12 - Taysha Gene Therapies Q3 net loss widens on higher R&D costs

  • Nov 12 - UK-US MeiraGTx Q3 net loss widens as R&D costs rise

  • Nov 10 - Germany's Immatics Q3 revenue misses estimates, net loss widens on higher spending


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on 4D Molecular Therapeutics

See all news